{
  "meta": {
    "title": "Cancer_Biology_-_3_Other_Hallmarks_Familial_Cancer_Syndromes",
    "url": "https://brainandscalpel.vercel.app/cancer-biology-3-other-hallmarks-familial-cancer-syndromes-d25bdff2.html",
    "scrapedAt": "2025-11-29T18:24:57.155Z"
  },
  "questions": [
    {
      "id": 19763,
      "choices": [
        {
          "id": 79013,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutation in BRCA1 </span></span></span></p>"
        },
        {
          "id": 79014,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amplification of HER2 </span></span></span></p>"
        },
        {
          "id": 79015,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loss of function mutation in VHL </span></span></span></p>"
        },
        {
          "id": 79016,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Activation of KRAS</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old patient presents with painless hematuria and flank pain. Imaging reveals a renal mass with characteristic features of clear cell renal cell carcinoma (RCC). Which of the following genetic alterations is MOST likely involved in the pathogenesis of this tumor?</span></span></p>",
      "unique_key": "Q1660386",
      "question_audio": null,
      "question_video": null,
      "map_id": 19596,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Loss of function mutation in VHL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clear cell RCC is strongly associated with inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. This leads to stabilization of hypoxia-inducible factor (HIF), promoting angiogenesis and tumor growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mutation in BRCA1:</span></strong><span style=\"font-size:12.0pt\"> BRCA1 is a tumor suppressor gene primarily associated with breast and ovarian cancers. While it can be involved in other cancers, it&#39;s not the primary driver of clear cell renal cell carcinoma (RCC).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Amplification of HER2:</span></strong><span style=\"font-size:12.0pt\"> HER2 amplification is a key feature of certain breast cancers and some other malignancies, but not clear cell RCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Activation of KRAS:</span></strong><span style=\"font-size:12.0pt\"> KRAS is an oncogene involved in various cancers, including some types of lung and colon cancer. It is not the hallmark of clear cell RCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The VHL gene plays a crucial role in oxygen sensing and regulation of blood vessel growth. When VHL is inactivated, it leads to the stabilization and activation of hypoxia-inducible factor (HIF), which promotes angiogenesis (new blood vessel formation) and tumor growth. This is why VHL loss-of-function mutations are so strongly linked to clear cell RCC.</span></span></p>",
      "correct_choice_id": 79015,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19764,
      "choices": [
        {
          "id": 79017,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Bevacizumab </span></span></span></p>"
        },
        {
          "id": 79018,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Cetuximab </span></span></span></p>"
        },
        {
          "id": 79019,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Trastuzumab </span></span></span></p>"
        },
        {
          "id": 79020,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is a monoclonal antibody targeting VEGF and is used in the treatment of various cancers, including renal cell carcinoma?</span></span></p>",
      "unique_key": "Q9244754",
      "question_audio": null,
      "question_video": null,
      "map_id": 19597,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Bevacizumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bevacizumab (Avastin) is a monoclonal antibody that binds to and inhibits VEGF, thereby suppressing angiogenesis and tumor growth. It is approved for use in several cancers, including renal cell carcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cetuximab:</span></strong><span style=\"font-size:12.0pt\"> This monoclonal antibody targets the epidermal growth factor receptor (EGFR), which is involved in cell growth and proliferation. It is not typically used to treat renal cell carcinoma. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Trastuzumab:</span></strong><span style=\"font-size:12.0pt\"> This monoclonal antibody targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some breast and stomach cancers. It is not indicated for renal cell carcinoma. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Rituximab:</span></strong><span style=\"font-size:12.0pt\"> This monoclonal antibody targets CD20, a protein found on the surface of B cells. It is used to treat certain types of lymphomas and leukemias but not renal cell carcinoma. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Bevacizumab stands out as the correct answer because it specifically targets VEGF, a key player in angiogenesis, which is a crucial process for tumor growth and survival. The other options are monoclonal antibodies targeting different receptors or proteins involved in other cancer types.</span></span></span></p>",
      "correct_choice_id": 79017,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19765,
      "choices": [
        {
          "id": 79021,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-1</span></span></p>"
        },
        {
          "id": 79022,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-L1</span></span></p>"
        },
        {
          "id": 79023,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CTLA-4</span></span></p>"
        },
        {
          "id": 79024,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CD80/86</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old man with metastatic melanoma has progressed on previous therapy. You are considering starting him on an immune checkpoint inhibitor along with nivolumab after which you are planning to keep him on nibolumab. Which of the following immune checkpoint molecules is the DIRECT target for the drug which you have planned to give for this patient along with nivolumab?</span></span></p>",
      "unique_key": "Q6417400",
      "question_audio": null,
      "question_video": null,
      "map_id": 19598,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) CTLA-4</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ipilimumab is a monoclonal antibody that specifically targets CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). CTLA-4 is an inhibitory receptor on T cells that, when bound to its ligands (CD80/CD86) on antigen-presenting cells, downregulates T-cell activation. By blocking CTLA-4, ipilimumab releases this inhibition, allowing T cells to more effectively recognize and attack cancer cells. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. PD-1:</span></strong><span style=\"font-size:12.0pt\"> PD-1 is another inhibitory checkpoint on T cells, but it&#39;s targeted by different drugs like nivolumab and pembrolizumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. PD-L1:</span></strong><span style=\"font-size:12.0pt\"> PD-L1 is the ligand for PD-1, and it&#39;s also targeted by different drugs like atezolizumab and durvalumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CD80/86:</span></strong><span style=\"font-size:12.0pt\"> These are the ligands for CTLA-4, but ipilimumab doesn&#39;t directly bind to them; it binds to CTLA-4 itself.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the specific targets of immune checkpoint inhibitors is crucial for selecting the right therapy for different types of cancer and managing potential immune-related side effects.</span></span></p>",
      "correct_choice_id": 79023,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19766,
      "choices": [
        {
          "id": 79025,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CTLA-4</span></span></p>"
        },
        {
          "id": 79026,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-1</span></span></p>"
        },
        {
          "id": 79027,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-L1</span></span></p>"
        },
        {
          "id": 79028,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LAG-3</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old woman with metastatic Merkel cell carcinoma has progressed on chemotherapy and is now being considered for immunotherapy. You plan to start him on an a monoclonal antibody designed to enhance the anti-tumor immune response. Which of the following immune checkpoint molecules is the DIRECT target of that drug?</span></span></p>",
      "unique_key": "Q1134409",
      "question_audio": null,
      "question_video": null,
      "map_id": 19599,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) PD-L1</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avelumab is a monoclonal antibody that specifically targets PD-L1 (Programmed Death-Ligand 1) on the surface of tumor cells. By binding to PD-L1, avelumab prevents it from interacting with PD-1 on T cells. This interaction normally acts as a &quot;brake&quot; on the immune system, preventing T cells from attacking the tumor. Blocking this interaction allows T cells to recognize and destroy the cancer cells more effectively.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CTLA-4:</span></strong><span style=\"font-size:12.0pt\"> CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4) is another immune checkpoint molecule, but it is targeted by different drugs like ipilimumab. Avelumab does not directly bind to or inhibit CTLA-4.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. PD-1:</span></strong><span style=\"font-size:12.0pt\"> PD-1 (Programmed Cell Death Protein 1) is the receptor on T cells that PD-L1 binds to. While avelumab indirectly affects PD-1 signaling by blocking its interaction with PD-L1, it doesn&#39;t directly bind to PD-1. Other drugs like nivolumab and pembrolizumab are designed to directly target PD-1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. LAG-3:</span></strong><span style=\"font-size:12.0pt\"> LAG-3 (Lymphocyte Activation Gene-3) is another inhibitory receptor on T cells that is being investigated as a target for immunotherapy. However, avelumab does not target LAG-3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> &nbsp;</u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Avelumab is a PD-L1 inhibitor used in the treatment of metastatic Merkel cell carcinoma and other cancers to unleash the body&#39;s immune system against tumors.</span></span></p>",
      "correct_choice_id": 79027,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19767,
      "choices": [
        {
          "id": 79029,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxidative phosphorylation</span></span></p>"
        },
        {
          "id": 79030,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Cori cycle </span></span></p>"
        },
        {
          "id": 79031,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Warburg effect</span></span></p>"
        },
        {
          "id": 79032,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gluconeogenesis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A researcher is studying the metabolic profile of cancer cells and notices that they primarily produce energy through glycolysis, even in the presence of oxygen. This phenomenon is BEST described as:</span></span></span></p>",
      "unique_key": "Q7911880",
      "question_audio": null,
      "question_video": null,
      "map_id": 19600,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) The Warburg effect</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Warburg effect is the observation that cancer cells preferentially utilize aerobic glycolysis for energy production. This is in contrast to normal cells, which typically rely on oxidative phosphorylation in the presence of oxygen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oxidative phosphorylation:</span></strong><span style=\"font-size:12.0pt\"> This is the normal process of energy production in cells with sufficient oxygen. It occurs in the mitochondria and is much more efficient at generating ATP than glycolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. The Cori cycle:</span></strong><span style=\"font-size:12.0pt\"> This is a metabolic pathway that involves the interconversion of lactate and glucose between the liver and muscles. While lactate is a byproduct of glycolysis, the Cori cycle itself isn&#39;t the primary energy production method in cancer cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Gluconeogenesis:</span></strong><span style=\"font-size:12.0pt\"> This is the process of synthesizing glucose from non-carbohydrate sources (like amino acids or lactate). While cancer cells may engage in gluconeogenesis, it&#39;s not the main energy-producing pathway they rely on.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Warburg effect is a hallmark of cancer metabolism and has implications for both cancer diagnosis and potential therapeutic targets.</span></span></span></p>",
      "correct_choice_id": 79031,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19768,
      "choices": [
        {
          "id": 79033,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin-dependent kinase inhibitors</span></span></p>"
        },
        {
          "id": 79034,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BH3 mimetics</span></span></p>"
        },
        {
          "id": 79035,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VEGF signaling inhibitors</span></span></p>"
        },
        {
          "id": 79036,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PARP inhibitors</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old woman with metastatic renal cell carcinoma has recently shown disease progression despite initial chemotherapy. Her oncologist is considering a treatment strategy to target the tumor&#39;s ability to create its own blood supply. Which of the following classes of drugs would be MOST appropriate for this purpose?</span></span></p>",
      "unique_key": "Q2162705",
      "question_audio": null,
      "question_video": null,
      "map_id": 19601,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) VEGF signaling inhibitors</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">VEGF (vascular endothelial growth factor) is a key signaling molecule that promotes angiogenesis, the formation of new blood vessels. By inhibiting VEGF signaling, these drugs can starve tumors of their blood supply, thereby slowing or stopping their growth and spread. This approach is often used in the treatment of metastatic renal cell carcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cyclin-dependent kinase inhibitors:</span></strong><span style=\"font-size:12.0pt\"> These drugs target cell cycle progression and are not directly involved in angiogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. BH3 mimetics:</span></strong><span style=\"font-size:12.0pt\"> These drugs target the apoptotic pathway to induce cell death and are not directly involved in angiogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PARP inhibitors:</span></strong><span style=\"font-size:12.0pt\"> These drugs exploit DNA repair defects in cancer cells and are not directly involved in angiogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">VEGF signaling inhibitors are a class of drugs that target angiogenesis, a crucial process for tumor growth and survival. They are used in the treatment of various cancers, including renal cell carcinoma.</span></span></span></p>",
      "correct_choice_id": 79035,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53463,
      "choices": [
        {
          "id": 213333,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neurofibromatosis type 2</span></span></p>"
        },
        {
          "id": 213334,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tuberous sclerosis complex</span></span></p>"
        },
        {
          "id": 213335,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von Hippel-Lindau disease</span></span></p>"
        },
        {
          "id": 213336,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Li-Fraumeni syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old male presents with progressive headaches, gait instability, and visual disturbances. MRI was taken and shown below. Patient also has, multiple retinal angiomas. His family history is notable for his father died of uncontrolled hypertension during his 50s and his paternal side uncle was diagnosed with a brain tumor and uncontrolled hypertension along with frequent anger outbursts seeking psychiatric counselling. Which of the following is the MOST likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-172814.jpg\" style=\"height:387px; width:400px\" /></span></span></p>",
      "unique_key": "Q1065130",
      "question_audio": null,
      "question_video": null,
      "map_id": 25267,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Von Hippel-Lindau disease</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of a cerebellar hemangioblastoma, retinal angiomas, and a strong family history of similar tumors (brain tumor in the paternal uncle) and possible pheochromocytoma (uncontrolled hypertension, anger outbursts suggesting catecholamine excess) strongly suggests Von Hippel-Lindau (VHL) disease. VHL disease is an autosomal dominant inherited disorder that predisposes individuals to a variety of tumors, including, Hemangioblastomas, Renal cell carcinoma, Pheochromocytoma. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Neurofibromatosis type 2:</span></strong><span style=\"font-size:12.0pt\"> This condition is associated with bilateral vestibular schwannomas (tumors of the nerve responsible for hearing and balance) and other nerve tumors, not the specific findings in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tuberous sclerosis complex:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is associated with benign tumors in various organs, including the brain, kidneys, heart, eyes, lungs, and skin. The characteristic brain tumors are cortical tubers and subependymal giant cell astrocytomas, not hemangioblastomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Li-Fraumeni syndrome:</span></strong><span style=\"font-size:12.0pt\"> This syndrome predisposes individuals to a wide range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. It is not typically associated with the specific combination of findings in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of a cerebellar hemangioblastoma and retinal angiomas, especially in conjunction with a suggestive family history, should raise strong suspicion for Von Hippel-Lindau disease. Early diagnosis and surveillance are crucial for managing this condition and preventing complications.</span></span></span></p>",
      "correct_choice_id": 213335,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53464,
      "choices": [
        {
          "id": 213337,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Li-Fraumeni syndrome</span></span></p>"
        },
        {
          "id": 213338,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von Hippel-Lindau disease</span></span></p>"
        },
        {
          "id": 213339,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hereditary diffuse gastric cancer</span></span></p>"
        },
        {
          "id": 213340,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lynch syndrome (HNPCC)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman presents with a family history of early-onset colon and endometrial cancer. Which of the following hereditary cancer syndromes is MOST likely in this patient?</span></span></p>",
      "unique_key": "Q5580758",
      "question_audio": null,
      "question_video": null,
      "map_id": 25268,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Lynch syndrome (HNPCC)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lynch syndrome is associated with an increased risk of colorectal and endometrial cancers, often at an early age. The patient&#39;s family history aligns with this syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Li-Fraumeni syndrome:</span></strong><span style=\"font-size:12.0pt\"> Li-Fraumeni syndrome is associated with a broader range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. While colon cancer can occur in Li-Fraumeni syndrome, the prominence of endometrial cancer in the family history makes Lynch syndrome more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Von Hippel-Lindau disease:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is primarily characterized by the development of hemangioblastomas, renal cell carcinomas, and pheochromocytomas. It&#39;s not typically associated with a strong family history of colon or endometrial cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hereditary diffuse gastric cancer:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is mainly linked to an increased risk of diffuse gastric cancer and lobular breast cancer. While other cancers can occur, the family history in this case points more towards Lynch syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> &nbsp;</u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lynch syndrome is an inherited cancer syndrome characterized by an increased risk of colorectal, endometrial, and other cancers.</span></span></span></p>",
      "correct_choice_id": 213340,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53465,
      "choices": [
        {
          "id": 213341,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRKAR1A </span></span></p>"
        },
        {
          "id": 213342,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN2A </span></span></p>"
        },
        {
          "id": 213343,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SDH </span></span></p>"
        },
        {
          "id": 213344,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MET</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old man presents with multiple pigmented skin lesions and cardiac myxomas. He also reports a family history of sudden cardiac death. Which gene is MOST likely to be mutated in this patient?</span></span></p>",
      "unique_key": "Q9113611",
      "question_audio": null,
      "question_video": null,
      "map_id": 25269,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) PRKAR1A</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of pigmented skin lesions, cardiac myxomas, and a family history of sudden cardiac death suggests Carney complex, which is caused by mutations in the PRKAR1A gene.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CDKN2A</span></strong><span style=\"font-size:12.0pt\">: This gene is associated with melanoma and pancreatic cancer in the context of familial atypical multiple mole melanoma (FAMMM) syndrome. While pigmented skin lesions can be present in FAMMM, cardiac myxomas and a family history of sudden cardiac death are not characteristic features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. SDH</span></strong><span style=\"font-size:12.0pt\">: Mutations in SDH genes are linked to hereditary paraganglioma-pheochromocytoma syndrome, which primarily manifests with tumors of the adrenal glands and nervous system. Cardiac myxomas and pigmented skin lesions are not associated with this syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. MET</span></strong><span style=\"font-size:12.0pt\">: MET mutations are involved in hereditary papillary renal cell carcinoma. This condition is not typically associated with cardiac myxomas or pigmented skin lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u>&nbsp; </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The specific constellation of findings in this patient, including pigmented skin lesions, cardiac myxomas, and a family history of sudden cardiac death, is strongly suggestive of Carney complex, a rare autosomal dominant disorder caused by mutations in the PRKAR1A gene.</span></span></p>",
      "correct_choice_id": 213341,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53466,
      "choices": [
        {
          "id": 213345,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastrinoma</span></span></p>"
        },
        {
          "id": 213346,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prolactinoma </span></span></p>"
        },
        {
          "id": 213347,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary thyroid carcinoma</span></span></p>"
        },
        {
          "id": 213348,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulinoma</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman presents with a history of recurrent kidney stones and hypercalcemia. Her family history is significant for her mother having a pituitary tumor and her brother having undergone surgery for a parathyroid adenoma. Given the patient&#39;s clinical presentation and family history, which of the following tumors is LEAST likely to be associated with her suspected diagnosis?</span></span></p>",
      "unique_key": "Q6885261",
      "question_audio": null,
      "question_video": null,
      "map_id": 25270,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Medullary thyroid carcinoma</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation of recurrent kidney stones and hypercalcemia, along with a family history of pituitary and parathyroid tumors, strongly suggests Multiple Endocrine Neoplasia type 1 (MEN1). MEN1 is characterized by tumors of the parathyroid glands (leading to hypercalcemia), pituitary gland, and pancreas (often gastrinomas or insulinomas).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Medullary thyroid carcinoma</span></strong><span style=\"font-size:12.0pt\"> is associated with Multiple Endocrine Neoplasia type 2 (MEN2), not MEN1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Gastrinoma:</span></strong><span style=\"font-size:12.0pt\"> Gastrinomas are tumors of the pancreas that secrete gastrin, leading to excessive stomach acid production and peptic ulcers. They are a common feature of MEN1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prolactinoma:</span></strong><span style=\"font-size:12.0pt\"> Prolactinomas are pituitary tumors that secrete prolactin, causing symptoms like irregular periods, infertility, and milk production in women. Pituitary tumors are a key component of MEN1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulinoma:</span></strong><span style=\"font-size:12.0pt\"> Insulinomas are pancreatic tumors that secrete insulin, leading to hypoglycemia. They are another common manifestation of MEN1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:&nbsp; </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The constellation of findings in this patient points strongly towards MEN1. While MEN1 can have a variety of manifestations, medullary thyroid carcinoma is a hallmark of MEN2 and is not typically associated with MEN1.</span></span></span></p>",
      "correct_choice_id": 213347,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53467,
      "choices": [
        {
          "id": 213349,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
        },
        {
          "id": 213350,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DNA crosslink repair</span></span></p>"
        },
        {
          "id": 213351,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
        },
        {
          "id": 213352,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mismatch repair (MMR)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 7-year-old boy is brought to the pediatrician due to concerns about his small stature and sun sensitivity. He has also had recurrent respiratory infections. On physical examination, he is noted to have a photosensitive rash on his face, microcephaly, and low body weight for his age. Which of the following DNA repair pathways is MOST likely deficient in this child?</span></span></span></p>",
      "unique_key": "Q3163636",
      "question_audio": null,
      "question_video": null,
      "map_id": 25271,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Homologous recombination (HR)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The child&#39;s clinical presentation, including short stature, photosensitive rash, microcephaly, immunodeficiency, and predisposition to leukemia and lymphoma, is highly suggestive of Bloom syndrome. Bloom syndrome is caused by mutations in the BLM gene, which encodes a protein essential for homologous recombination (HR). HR is a critical DNA repair mechanism that repairs double-strand DNA breaks. Defects in HR lead to genomic instability and increased susceptibility to cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. DNA crosslink repair:</span></strong><span style=\"font-size:12.0pt\"> Defects in DNA crosslink repair are seen in Fanconi anemia, which presents with bone marrow failure, developmental abnormalities, and increased risk of leukemia, but not the other features seen in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> NHEJ is another DNA repair pathway that repairs double-strand breaks. While important for maintaining genomic stability, it&#39;s not the primary pathway affected in Bloom syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Mismatch repair (MMR):</span></strong><span style=\"font-size:12.0pt\"> MMR corrects errors that occur during DNA replication. Defects in MMR are seen in Lynch syndrome, which is associated with an increased risk of colorectal and other cancers, but not the characteristic features of Bloom syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bloom syndrome is a rare genetic disorder characterized by growth retardation, sun sensitivity, immunodeficiency, and predisposition to various cancers. It is caused by mutations in the BLM gene, which leads to defective homologous recombination and genomic instability.</span></span></span></p>",
      "correct_choice_id": 213349,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53468,
      "choices": [
        {
          "id": 213353,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ataxia-telangiectasia (AT)</span></span></p>"
        },
        {
          "id": 213354,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bloom syndrome (BLMS)</span></span></p>"
        },
        {
          "id": 213355,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fanconi anemia (FA)</span></span></p>"
        },
        {
          "id": 213356,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Werner syndrome (WRN)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman presents with premature aging, bilateral cataracts, and diabetes mellitus. She also has a family history of early-onset cancer. On examination, you observe that she has a bird-like peculiar facial feature. Which of the following genetic disorders is MOST likely?</span></span></p>",
      "unique_key": "Q3293565",
      "question_audio": null,
      "question_video": null,
      "map_id": 25272,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Werner syndrome (WRN)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of premature aging, cataracts, diabetes, and a family history of cancer strongly suggests Werner syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ataxia-telangiectasia (AT):</span></strong><span style=\"font-size:12.0pt\"> This condition presents in childhood with ataxia (uncoordinated movements), telangiectasias (dilated blood vessels), and immune deficiency. While it also predisposes to cancer, the premature aging features and cataracts are not characteristic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bloom syndrome (BLMS):</span></strong><span style=\"font-size:12.0pt\"> Bloom syndrome is also associated with an increased cancer risk and sun sensitivity, but the hallmark feature is short stature, not premature aging or cataracts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fanconi anemia (FA):</span></strong><span style=\"font-size:12.0pt\"> This condition is primarily characterized by bone marrow failure and an increased risk of leukemia and other cancers. Premature aging and cataracts are not typical features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of premature aging, cataracts, diabetes, a family history of early-onset cancer, and a &quot;bird-like&quot; facial appearance strongly supports the diagnosis of Werner syndrome.</span></span></span></p>",
      "correct_choice_id": 213356,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}